Patient adherence to and tolerability of self-administered interferon β-1a using an electronic autoinjection device: a multicentre, open-label, phase IV study

Table 1 Baseline characteristics according to pre-study DMD treatment (intent-to-treat population; n = 119)

	Number (%) of patients	Age, years	Duration of MS, years	EDSS score*	PASAT score^†	HADS Anxiety score^‡	HADS Depression score^‡
Pre-study DMD		Median (range); 95% confidence interval
im IFN β-1a	75 (63.0)	39	5	2^¶	42.5	7	5
		(19-58)	(0-22)	(0-5.5)	(5-60)	(0-20)	(0-20)
		35.6, 39.9	4.9, 7.3	1.9, 2.4	40.0, 45.3	6.9, 9.2	4.9, 7.0
IFN β-1b	26 (21.8)	37	3.5	1.5	48	7	3.5
		(20-52)	(0-22)	(0-6)	(24-59)	(0-13)	(0-15)
		34.1, 42.4	3.1, 8.6	1.3, 2.4	42.6, 50.8	5.0, 7.8	3.5, 7.1
Glatiramer acetate	15 (12.6)	41	4	1.5	35	7	3
		(18-55)	(1-8)	(0-4.5)	(18-52)	(0-14)	(0-12)
		31.7, 44.5	2.7, 5.3	1.3, 2.9	30.5, 41.9	3.8, 9.0	2.3, 7.0
sc IFN β-1a	3 (2.5)	35	6	3	46	4	6
		(22-43)	(6-11)	(2-4)	(25-51)	(4-10)	(2-6)
		7.0, 59.6	0.5, 14.8	0.5, 5.5	6.4, 74.9	-2.6, 14.6	-1.1, 10.4

*Range: 0 (no disability) to 10 (severe disability resulting in death)
^†Range: 0 to 60 (higher scores indicate better cognitive function)
^‡Range: 0 to 21 (higher scores indicate more severe symptoms)
^¶n = 72
DMD disease-modifying drug, EDSS Expanded Disability Status Scale, HADS Hospital Anxiety and Depression Scale, IFN interferon, im intramuscular, MS multiple sclerosis, PASAT Paced Auditory Serial Addition Task, sc subcutaneous

ISSN: 1471-2377